| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1586 | 2011 |
| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ... Leukemia 13 (12), 1901-1928, 1999 | 1536 | 1999 |
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1344 | 2008 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1296 | 2011 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1222 | 2011 |
| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1011 | 2015 |
| An inducible caspase 9 safety switch for T-cell therapy KC Straathof, MA Pule, P Yotnda, G Dotti, EF Vanin, MK Brenner, ... Blood 105 (11), 4247-4254, 2005 | 799 | 2005 |
| In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment Q Chen, C Wang, X Zhang, G Chen, Q Hu, H Li, J Wang, D Wen, Y Zhang, ... Nature nanotechnology 14 (1), 89-97, 2019 | 770 | 2019 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15 Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, ... Blood, The Journal of the American Society of Hematology 123 (24), 3750-3759, 2014 | 733 | 2014 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 703 | 2017 |
| Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes I Caruana, B Savoldo, V Hoyos, G Weber, H Liu, ES Kim, MM Ittmann, ... Nature medicine 21 (5), 524-529, 2015 | 700 | 2015 |
| Design and development of therapies using chimeric antigen receptor‐expressing T cells G Dotti, S Gottschalk, B Savoldo, MK Brenner Immunological reviews 257 (1), 107-126, 2014 | 647 | 2014 |
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape M Hegde, M Mukherjee, Z Grada, A Pignata, D Landi, SA Navai, ... The Journal of clinical investigation 126 (8), 3036-3052, 2016 | 632 | 2016 |
| Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, ... Leukemia 32 (2), 520-531, 2018 | 624 | 2018 |
| Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, ... Leukemia 24 (6), 1160-1170, 2010 | 612 | 2010 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 586 | 2013 |
| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ... Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009 | 578 | 2009 |
| A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells MA Pulè, KC Straathof, G Dotti, HE Heslop, CM Rooney, MK Brenner Molecular Therapy 12 (5), 933-941, 2005 | 576 | 2005 |
| TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, ... Molecular Therapy-Nucleic Acids 2, 2013 | 513 | 2013 |
| In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy C Wang, J Wang, X Zhang, S Yu, D Wen, Q Hu, Y Ye, H Bomba, X Hu, ... Science translational medicine 10 (429), eaan3682, 2018 | 492 | 2018 |
